Stay updated with breaking news from Bay Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Celregen Therapeutics signed a $100 million agreement to in-license China rights for a novel therapy that uses induced Pluripotent Stem Cells to repair bullous keratopathy.
/PRNewswire/ -- Great Bay Bio (hereinafter referred to as "GBB") is pleased to announce today the completion of its USD 15M Pre-series B funding led by Tiger...
/PRNewswire/ -- Great Bay Bio (GBB), an AI-enabled biotechnology company, announces the participation of FutureX Capital in its Series A round fundraising....
/PRNewswire/ -- Great Bay Bio (GBB), an AI-enabled biotechnology company, announces the participation of FutureX Capital in its Series A round fundraising....
Press release content from PR Newswire. The AP news staff was not involved in its creation.